New activity is brewing for Sonnet BioTherapeutics Holdings ( (SONN) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sonnet BioTherapeutics Holdings, Inc. has announced a special meeting for its stockholders to vote on a significant business combination agreement with Rorschach I LLC and Hyperliquid Strategies Inc. This agreement, initially entered on July 11, 2025, and amended on September 22, 2025, involves a series of mergers that will result in Sonnet becoming a wholly owned subsidiary of a new entity, Pubco. The transaction is expected to issue approximately 155 million shares of Pubco Common Stock and warrants for an additional 20 million shares, reflecting a strategic move to consolidate operations and potentially enhance market positioning. The meeting is set for November 18, 2025, and will be held virtually.
The most recent analyst rating on (SONN) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Sonnet BioTherapeutics Holdings stock, see the SONN Stock Forecast page.
Spark’s Take on SONN Stock
According to Spark, TipRanks’ AI Analyst, SONN is a Underperform.
Sonnet BioTherapeutics Holdings is facing severe financial difficulties, with declining revenues, negative profitability, and high leverage being the most significant concerns. Technical analysis shows mixed signals, with some potential for short-term recovery. However, the poor valuation due to negative earnings and lack of dividends further weighs down the stock’s attractiveness.
To see Spark’s full report on SONN stock, click here.
More about Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings, Inc. operates in the biotechnology industry, focusing on the development of innovative biologic drugs. The company is involved in creating targeted therapies for cancer treatment, leveraging its proprietary platform to enhance the efficacy of biologic drugs.
Average Trading Volume: 899,400
Technical Sentiment Signal: Sell
Current Market Cap: $33.73M
See more data about SONN stock on TipRanks’ Stock Analysis page.